Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

on with docetaxel/prednisone, measuring the effect of custirsen on serum clusterin levels and describing time to progression and overall patient survival. Baseline characteristics were well balanced between the treatment arms.

About Custirsen

Custirsen is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance. In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen. The global Phase 3 clinical programs include both the ongoing SATURN Phase 3 trial assessing durable pain palliation as the primary endpoint for second-line chemotherapy in men with metastatic CRPC and the upcoming SYNERGY Phase 3 trial assessing survival as the primary endpoint in men with metastatic CRPC receiving first-line chemotherapy. A third Phase 3 trial assessing survival as the primary endpoint in first-line treatment of advanced, unresectable non-small cell lung cancer (NSCLC) is also planned as part of the global clinical program to commercialize custirsen.

More information on the SATURN trial is available on the OncoGenex website at http://oncogenex.com/clinicalTrials/index.html.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA). Both the Prostate Cancer SATURN trial and the SYNERGY trial are being conducted through the Special Protocol Assessment (SPA) process. In addition, the European Medicines Agency indicated that the Committee for Medicinal Products for Human Use was in overall agreement with the custirsen development plan for commercialization.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... FREMONT, Calif., June 16 Microfluidic Systems, a ... number 7,541,166, entitled "Sonication to Selectively Lyse Different ... process of differential extraction of male/female DNA from ... a wide variety of biological sample processes for ...
... experts to present best practices for improving drug safety and ... June 16 Covance Inc. is pleased to announce the ... Drug Information Association,s (DIA) 45th Annual Meeting ... , , The DIA Annual Meeting is the ...
... Six prestigious members of the National Institutes of Health ... ), the nation,s leading online jobs board and careers ... NIH has the highest number of post-doctoral professionals at ... organizations that have joined include the National Institute of ...
Cached Biology Technology:MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2Covance to Present at the Drug Information Association's 45th Annual Meeting 2Covance to Present at the Drug Information Association's 45th Annual Meeting 3Covance to Present at the Drug Information Association's 45th Annual Meeting 4Covance to Present at the Drug Information Association's 45th Annual Meeting 5National Institutes of Health Join Nation's Leading Postgrad Bio Jobs Board 2National Institutes of Health Join Nation's Leading Postgrad Bio Jobs Board 3
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... 2014 -- Bay Area Lyme Foundation, which aims to ... cure, applauds new research published in an upcoming issue ... Tick-borne Diseases . The findings show that ticks ... throughout the year, making the threat of Lyme disease ... Department of Public Health (CDPH) Vector-borne Disease Section and ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Harvard Medical School and Massachusetts Institute of Technology (MIT), ... have shown for the first time that targeted drug ... acid ligands (referred to as aptamers) are short DNA ... with high specificity and affinity; analogous to monoclonal antibodies. ...
... results from researchers at Harvard Medical School and Massachusetts ... European Cancer Conference (ECCO) have shown for the first ... conjugates. , Nucleic acid ligands (referred to as ... bind to target antigens with high specificity and affinity; ...
... to suppress HIV replication and has dramatically improved the ... the existence of viral reservoirs precludes the complete elimination ... appearing on November 1 in The Journal of Clinical ... new insight into the eradication of HIV in infected ...
Cached Biology News:Researchers use 'trickery' to create immune response against melanoma 2Researchers use 'trickery' to create immune response against melanoma 3Researchers use 'trickery' to create immune response against melanoma 4Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 2Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 3Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates 4
... Ideal for cell culture scale-up, these ... 10 7 - 10 9 range ... bottles or spinner flasks. • High mechanical ... leak tested prior to shipping • Certified ...
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
MAb to Desmoplakin I & II Desmoplakin I & II...
Biology Products: